Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The investigators want to develop a gene expression profile the for prediction the chemotherapeutic response of patients with metastatic breast cancer.
Condition or disease
Breast NeoplasmsNeoplasm Metastasis
Metastatic breast cancer tissue is obtained from core needle biopsies pretreatment and is flash frozen and stored at -70℃ until processing.
After patients received docetaxel combination thiotepa for two cycles, response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide the cancers into two groups—sensitive and resistant tumours.
The gene expression in metastatic breast cancer tissue sample is detected by microarray to screen gene markers that are differently expressed between groups
Statistical analysis is performed using unsupervised hierarchical cluster.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
female patients with metastatic breast cancer treated by Docetaxel-based chemotherapy
Patients should be histologically confirmed with metastatic breast cancer;
Patients who had completed the planned chemotherapy regimen with no major protocol violation;
an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
At least one measurable lesion;
Normal cardiac, hepatic, renal and bone marrow functions;
Life expectancy ≥3 months;
Discontinuity of previous chemotherapy for a minimum of 4 weeks.
previous history of other malignancies;
previous surgery history on the needle biopsy organ;
Central nervous system metastases;
Serious or uncontrolled concurrent medical illness.